Analysts Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $69.17

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have received an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $70.50.

A number of research analysts have issued reports on ELVN shares. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Mizuho lifted their target price on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. JonesTrading boosted their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th.

Enliven Therapeutics Stock Up 0.3%

Shares of Enliven Therapeutics stock opened at $52.95 on Tuesday. The company’s fifty day simple moving average is $45.49 and its two-hundred day simple moving average is $37.27. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $54.88. The firm has a market cap of $3.22 billion, a PE ratio of -31.71 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. As a group, sell-side analysts expect that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total value of $263,588.40. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $2,233,800. This represents a 10.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director owned 51,884 shares in the company, valued at approximately $1,792,073.36. This trade represents a 16.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 26,018 shares of company stock valued at $1,113,888 in the last three months. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently made changes to their positions in the stock. Commodore Capital LP raised its stake in Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after buying an additional 17,809 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc grew its stake in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after acquiring an additional 418,673 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after acquiring an additional 142,378 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Enliven Therapeutics by 9.1% during the fourth quarter. State Street Corp now owns 1,052,862 shares of the company’s stock valued at $16,214,000 after acquiring an additional 87,725 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.